Redirecting to https://www.wallstreet-online.de/nachricht/20239389-oric-pharmaceuticals-announces-enozertinib-oric-114-late-breaking-oral-presentations-egfr-atypical-and-egfr-exon-20-nsclc-at-the-esmo-asia-congress-2025